Avadel Pharmaceuticals — Investor Presentation (November 2017)
85 slides from Avadel Pharmaceuticals's investor presentation, Nov 13, 2017
Slide 1: Noctiva Analyst and Investor Presentation
1 Noctiva™ Analyst and Investor Presentation Monday, November 13, 2017
Slide 2: Safe Harbor
2 Safe Harbor This presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words “will,” “may,” “believe,” “expect,” “anticipate,” “estimate,” “project” and similar expressions, an
Slide 3: Avadel: a new chapter
3 Avadel: a new chapter o Closing our history of solely focusing on drug delivery o Transitioning from dependence on partners to self-funded innovation o Welcoming long-term and sustainable growth o Committing to building shareholder value through diversified specialty product offerings o Welcome an
Slide 4: Agenda
4 Agenda o Nocturia market overview – Condition and its consequences; Alan Wein, MD, PhD(Hon) FACS – Current treatment options; Roger Dmochowski, MD, MMHC, FACS o Noctiva overview – Innovation and the invention; Samuel Herschkowitz, MD, Chief Executive Officer, Serenity Pharmaceuticals, LLC – Clinic
Slide 5: Nocturia, the Condition and Its Consequences
5 Nocturia, the Condition and Its Consequences Alan J. Wein, MD, PhD(Hon), FACS Founders Professor and Emeritus Chief of Urology Director, Residency Program in Urology University of Pennsylvania Perelman School of Medicine PENN Medicine
Slide 6: Nocturia is highly prevalent and under-recognized
6 • Highly prevalent – impacts over 40 million Americans1 • Under-recognized as a distinct condition • Associated with significant sleep disruption • Increasingly bothersome based on number of voids per night • Linked to health complications and a negative impact on quality of life Nocturia is • Sim
Slide 7: Prevalence, diagnosis, and treatment rates of nocturia
7 Prevalence, diagnosis, and treatment rates of nocturia1-7 1. Bosch JLH, Weiss JP. The prevalence and causes of nocturia. J Urol. 2010;184(2):440-446. 2. QuintilesIMS Secondary Research. 3. Lee LK, Goren A, Zou KH, et al. Potential benefits of diagnosis and treatment on health outcomes among elderl
Slide 8: Prevalence and frequency of nocturia increase with age
8 The prevalence and frequency of nocturia increase with age1 Popu la ti o n -b a sed P re v a le n ce ( % ) 1. Markland AD, Richter HE, Fwu CW, Eggers P, Kusek JW. Prevalence and trends of urinary incontinence in adults in the United States, 2001 to 2008. J Urol. 2011;186(2):589-593. Age (Years) 0
Slide 9: Nocturia impacts both men and women
9 Nocturia impacts both men and women 1. Coyne KS, Zhou Z, Bhattacharyya SK, Thompson CL, Dhawan R, Versi E. The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int. 2003;92(9):948-954. P re v a le n ce ( % ) Female Age (Years)
Slide 10: Multiple factors can cause nocturia
10 Multiple factors can cause nocturia1 1. Wein A, Lose GR, Fonda D. Nocturia in men, women and the elderly: a practical approach. Br J Urol. 2002;90(suppl 3):28-31. Nocturia Sleep disturbances Psychological disturbances Bladder- storage problems Mixed Nocturnal polyuria • Overproduction of urine at
Slide 11: Nocturnal polyuria is present in majority of nocturia patients
11 Nocturnal polyuria (NP) is present in the majority of patients with nocturia *Males only. 1. Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn. 2004;23(4):322-330. 2. Chang SC
Slide 12: Degree of bother increases with number of episodes
12 0 10 20 30 40 50 60 1 2 3 4 or more No bother Small bother Moderate bother Major bother N=3474 1. Tikkinen KA, Johnson TM, Tammela TL, et al. Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. Eur Urol. 2010;57(3):488-496. 2. Chapple CR,
Slide 13: The first few hours of sleep are the most important
13 The first few hours of sleep are the most important1-3 o Deep, slow-wave, restorative sleep occurs during the first hours, while less restorative, lighter sleep predominates later o Waking during the first 3 to 4 hours is more likely to leave a person groggy/tired the next day 1. Kerrebroeck PV,
Slide 14: Nocturia and sleep disruption have far-reaching health effects
14 Nocturia and sleep disruption have far-reaching health effects1-6 1. Kobelt G, Borgstrom F, Mattiassön A. Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. BJU Int. 2003;91(3):190-195. 2. Asplund R. Hip fractures, nocturia, and nocturnal pol
Slide 15: Nocturia significantly impacts daily functioning
15 Nocturia significantly impacts daily functioning of both women and men1,2 0.7 0.8 0.9 1.0 0.9 0.8 0.7 *** *** *** *** *** *** *** *** *** *** *** *** ** *** *** *** ****** *** *** *** *** *** *** *** *** *** * Men Women No nocturia 1 episode/night 2 episodes/night ≥3 episodes/night L e v e l V a
Slide 16: Nocturia impacts daytime sleepiness, naps, and sick leave
16 Nocturia impacts daytime sleepiness, naps, and sick leave1 0 5 10 15 20 25 30 35 40 Moderate Severe 5 to 7 days/wk 3 to 4 days/wk Sick Leave P ropo rtion o f P at ient s Every night (n=2056) 5 to 6 nights (n=402) 3 to 4 nights (n=706) <3 nights (n=5773) Daytime Sleepiness Naps Nocturnal Awakening
Slide 17: Nocturia affects daytime activity and work productivity
17 Nocturia affects daytime activity and work productivity1 1. Kobelt G, Borgstrom F, Mattiassön A. Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. BJU Int. 2003;91(3):190-195. Increased work impairment (assessed using WPAI) Increased impairm
Slide 18: Nocturia: falls and hip fractures
18 Nocturia: falls and hip fractures1,2,3 oNocturia increases risk of a fall 25% over 3 years oOdds Ratio (OR) for a fall increases from 1.84 (Nx2) to 2.15 (Nx3) oOR for hip fracture – 1.36 in older men, N ≥ 2 – 1.8 in older men, N ≥ 3 1. Stewart et al. J Am Ger Soc, 1992 2. Bliwise et al. Sleep Med
Slide 19: Nocturia is a strong predictor of mortality
19 Nocturia is a strong predictor of mortality1 1. Kupelian V, Fitzgerald MP, Kaplan SA, Norgaard JP, Chiu GR, Rosen RC. Association of nocturia and mortality: results from the Third National Health and Nutrition Examination Survey. J Urol. 2011;185(2):571-577. ≥2 voids/night are associated with wor
Slide 20: Nocturia, Current Treatment
20 Nocturia, Current Treatment Roger Dmochowski, MD, MMHC, FACS Professor of Urology and Gynecology Vanderbilt University Medical Center
Slide 21: Nocturia improvements contribute to quality of life
21 “Improvements in nocturia contribute considerably to overall improvements in health-related quality of life.”1 1. Van Dijk MM, Debruyne WH, Rosette DL, Michel MC. The role of nocturia in the quality of life of men with lower urinary tract symptoms. BJU Int. 2010;105(8):1141-1146. ~Van Dijk, et al
Slide 22: Simple logic to decrease nocturia
22 Simple logic to decrease nocturia Decrease bladder activation on motor and/or sensory side of the micturition cycle (OAB, BPH, Combination) Decrease significant residual urine volume and thereby improve nocturnal storage capacity (BPH) Decrease nocturnal urine production
Slide 23: Nocturia therapies: outcome indicators
23 Nocturia therapies: outcome indicators Number of nocturia episodes per night Time to first awakening (FSUP) QoL indicators Long-term decrease in adverse events (parallel variation)
Slide 24: Nocturia treatment
24 Nocturia treatment • Preemptive voiding • Nocturnal and late afternoon dehydration • Dietary restrictions (eg, caffeine, alcohol) • Medication timing (late afternoon diuretic) • Compression stockings • Afternoon and evening leg elevation Behavior/lifestyle modifications Target the most prominent
Slide 25: Current treatment options do not effectively treat nocturia
25 But current treatment options do not effectively treat nocturia “Medications to treat LUTS in men…were not significantly better than placebo in short-term use.”1 EAU Guidelines Committee “Data on OAB medications generally had a female predominant population and were not significantly better than
Slide 26: OAB and BPH therapies do not address the source of nocturia
26 OAB and BPH therapies do not address the true source of nocturia Benign prostatic hyperplasia (BPH) Overactive bladder (OAB) Nocturia due to nocturnal polyuria 1. Asseldonk BV, Barkin J, Elterman DS. Medical therapy for benign prostatic hyperplasia: a review. Can J Urol. 2015;22(suppl 1):7-17. 2.
Slide 27: BPH/OAB therapies have limited effect on nocturia
27 BPH/OAB therapies have limited effect on nocturia 1. Noctiva Quantitative Market Research Assessment Patient Final Report. April 16, 2014. 2. Johnson TM, Jones K, Williford WO, Kutner MH, Issa MM, Lepor H. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analy
Slide 28: Nocturia treatment considerations
28 Nocturia treatment considerations o BPH and OAB therapies do not adequately address the underlying cause of nocturia in a majority of patients: nocturnal polyuria o Improvement in nocturia is therefore often minimal with BPH/OAB therapies o Antidiuretic therapy with desmopressin targets nocturnal
Slide 29: Desmopressin is effective for the treatment of nocturia
29 Desmopressin is effective for the treatment of nocturia1 o Oral and sublingual formulations of desmopressin were associated with an increased risk of hyponatremia o Desmopressin works at the source of nocturia by increasing urea reabsorption in the medullary collecting tubule Study Effective dose
Slide 30: Current nocturia therapy has varying effectiveness
30 Current nocturia therapy has varying effectiveness Has not shown durable efficacy in clinical practice Behavioral modification have marginal efficacy for treating nocturia Drugs for OAB and BPH Effective for nocturia, but use limited by safety concerns Desmopressin
Slide 31: Conclusions
31 Conclusions oNocturia is an important medical condition associated with significant morbidity oNocturia increases the risk of falls and is a strong predictor of mortality oNocturia disrupts normal sleep, causes daytime fatigue and loss of productivity, and impairs ability to perform daily activit
Slide 32: Noctiva, the Invention
32 Noctiva, the Invention Samuel Herschkowtiz, MD Chief Executive Officer, Serenity Pharmaceuticals, LLC Noctiva is not yet available for prescription.
Slide 33: The challenge: limiting duration of desmopressin action
33 The challenge: To limit the duration of antidiuretic action of desmopressin to 4 to 6 hours at night in order to achieve efficacy and improve the safety profile (minimize risk of hyponatremia)
Slide 34: Noctiva (desmopressin acetate) product overview
34 Noctiva (desmopressin acetate) product overview First-in-class product1 For the treatment of nocturia due to nocturnal polyuria in adults who awaken 2 or more times per night to void2 FDA-approved March 3, 20171 Avadel secured exclusive rights September 20177 Decreases the number of nighttime voi
Slide 35: The solution: Noctiva
35 The solution: Noctiva Very low dose of desmopressin1 Engineered to achieve highly consistent absorption from dose to dose and from patient to patient1 Pharmacokinetic coefficient of variation is comparable to subcutaneous administration2 Patented permeation enhancer (CPD) results in higher bioava
Slide 36: Noctiva was designed specifically for the patient with nocturia
36 Noctiva was designed specifically for the patient with nocturia* o The novel and patented Noctiva formulation produces: High bioavailability1 (~8%) Peak plasma concentration <10 pg/mL2 Short duration of action2 (4-6 hours) Unique spray pattern3 (centrifugal, donut-shaped droplet distribution, whi
Slide 37: Noctiva vs aqueous-based nasal spray
37 Noctiva vs aqueous-based nasal spray1 Aqueous base Noctiva Plume geometry Spray pattern 1. Data on file. Avadel Specialty Pharmaceuticals, LLC.
Slide 38: Overview of Clinical Data
38 Overview of Clinical Data Seymour Fein, MD Chief Medical Officer, Serenity Pharmaceuticals, LLC Noctiva is not yet available for prescription.
Slide 39: Noctiva studied in clinical trials in over 2300 patients
39 Noctiva has been studied in clinical trials in over 2300 patients Open-label studies ELD (N=32) 56-day study in elderly patients (75 to 85 years) OL1 (N=376) Long-term, 43 weeks DB3-A2 (N=393) 126-week extension study Pivotal Phase III studies DB3 (N=745) 99 days DB4 (N=797) 99 days Initial Phase
Slide 40: Overview of Pivotal Clinical Study Data
40 Overview of Pivotal Clinical Study Data 2 Phase III randomized, double-blind, placebo-controlled, parallel-group, multicenter, clinical studies (DB3 and DB4) Noctiva is not yet available for prescription.
Slide 41: Change in mean number of nocturic episodes per night
41 Change in mean number of nocturic episodes per night1 -1.2 -1.4 -1.5 -1.6 -1.4 -1.2 -1 -0.8 -0.6 -0.4 -0.2 0 LS M ean Cha n ge From B asel in e DB3/DB4 combined results NOCTIVA 1.66 mcg N=342 NOCTIVA 0.83 mcg N=354 Placebo N=349 Baseline (LS mean) 3.3 3.4 3.3 Difference from placebo – -0.2 -0.3 P
Slide 42: Patients achieving ≥50% reduction in nocturic episodes
42 Percentage of patients achieving ≥50% reduction in nocturic episodes1 27.5 37.3 48.0 0 10 20 30 40 50 Percen ta g e o f P a ti en ts Difference from placebo (%) – 9.8 20.5 P value vs placebo .0055 <.0001 Co-primary Efficacy Endpoint ITT population with nocturia due to nocturnal polyuria. DB3/DB4
Slide 43: Reduction in nocturic episodes by gender, age, etiology
43 1.66 mcg minus Placebo 0.83 mcg minus Placebo Overall Sex Male Female Age <65 years ≥65 years Nocturia etiology Nocturnal polyuria No nocturnal polyuria OAB by history BPH by history Favors SER120 Favors Placebo Co-primary Efficacy Endpoint Reduction in mean number of nocturic episodes per night
Slide 44: Time from bedtime to first nocturic episode
44 Time From Bedtime to 1st Nocturic Episode 0 60 120 180 240 300 Change in Time From Bedtime to 1st Nocturic Episode Minutes (SE) P<0.0001 P<0.0001 Placebo (N=349) NOCTIVA 0.83 mcg (N=354) NOCTIVA 1.66 mcg (N=342) Secondary Efficacy Endpoint Change in time from bedtime to first nocturic episode1 IT
Slide 45: Change in percentage of nights with 0 or ≤1 episode
45 Secondary Efficacy Endpoint Change in percentage of nights with 0 or ≤1 nocturic episode1 0 5 10 15 20 25 30 35 40 45 50 Cha n ge From B asel ine in Percen ta g e o f N ig h ts 0 nocturic episodes, on a per-patient basis NOCTIVA 1.66 mcg N=342 NOCTIVA 0.83 mcg N=354 Placebo N=349 NOCTIVA 1.66 mcg
Slide 46: Reduction in nocturnal urine volume
46 Reduction in nocturnal urine volume1 -350 -300 -250 -200 -150 -100 -50 0 mL (S E ) DB3/DB4 combined results NOCTIVA 1.66 mcg N=342 NOCTIVA 0.83 mcg N=354 Placebo N=349 Secondary Efficacy Endpoint Patients using Noctiva produced significantly less urine at night ITT population with nocturia due to
Slide 47: Magnitude of change in responders
47 Magnitude of change in responders for various efficacy variables1 2.9 5.3 0 1 2 3 4 5 6 Change in Time to First Void Time to First Void Change in Time to First Episode and Time to First Episode -2.1 -2.5 -2.0 -1.5 -1.0 -0.5 0.0 Mean Reduction in Nocturic Episodes 20.08 76.20 0 10 20 30 40 50 60 7
Slide 48: Durability: reduction in mean nocturic episodes per night
48 -1.3 -1.6 -1.7 -1.9 -1.8 -1.9 -1.8 -1.8 -1.9 -1.9 -2.0 -1.9 -2.1 -2.0 -1.9 -2.0 -2.0 -2.1 -2.5 -2 -1.5 -1 -0.5 0 0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 90 96 102 108 114 120 126 Time (weeks) Noctiva 1.66 mcg long-term Durability: reduction in mean nocturic episodes per night1 Open-Label, Long
Slide 49: INTU items: placebo-subtracted mean change scores
49 INTU items: placebo-subtracted mean change scores ITT population1 1.66 mcg minus Placebo 0.83 mcg minus Placebo Overall Impact Score Daytime Impact Score Item 1: Concentration Item 2: Tiredness Item 3: Completing Activities Item 4: Irritability Item 6: AM Restfulness Item 10: AM Drowsiness Nightt
Slide 50: O'Brien multivariate rank analysis for INTU items
50 O’Brien multivariate rank analysis for INTU items: change from screening to treatment1 Axis Length is Mean Rank. The highest rank represents the greatest reduction among all change values of an outcome variable in the pooled set of 2 samples. Concentration Tiredness Completing Activities Irritabi
Slide 51: Integrated Summary of Safety
51 Integrated Summary of Safety Overview of hyponatremia data
Slide 52: Incidence of serum sodium concentration below normal range
52 5.2 0 0.3 9.3 2.3 0 12.3 2.1 1.5 0 5 10 15 20 25 130-134 mmol/L 126-129 mmol/L ≤125 mmol/L Placebo Noctiva 0.83 mcg Noctiva 1.66 mcg No. of patients 18/349 33/354 42/341 1/349 8/354 7/341 1/349 0/354 5/341 Serum Sodium Concentration (mmol/L) Pe rc en ta ge o f P a tie n ts Incidence of serum sodi
Slide 53: Incidence of patients with nadir serum sodium
53 Note: The N (%) from 0.75-mcg group is based on the number of patients from the ELD and OL1 studies. Treatment period for the ELD study was 8 weeks while the treatment period for the OL1 study was 43 weeks. Incidence of patients with nadir serum sodium post baseline by serum sodium range1 ISS ELD
Slide 54: Noctiva Indication and Boxed Warning
54 NoctivaTM (desmopressin acetate) Indication and Boxed Warning o INDICATIONS AND USAGE: Noctiva is a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. – Limitation of Use: Not studied in patients younger th
Slide 55: Noctiva Important Safety Information (continued)
55 Noctiva Important Safety Information (continued) o CONTRAINDICATIONS: Hyponatremia or a history of hyponatremia, polydipsia, primary nocturnal enuresis, concomitant use with loop diuretics or systemic or inhaled glucocorticoids, estimated glomerular filtration rate below 50 mL/min/1.73 m2, Syndro
Slide 56: A Clinician's Perspective
56 A Clinician’s Perspective Steve A. Kaplan, MD Professor of Urology, Icahn School of Medicine at Mount Sinai Director, Benign Urologic Diseases and The Men’s Health Program, Mount Sinai Health System Noctiva is not yet available for prescription.
Slide 57: Summary point: Nocturia is an under-recognized condition
57 Summary point 1 o Out of an estimated 40 million Americans with nocturia, only approximately 11 million have been diagnosed1-4 o Prevalence increases with age5 o Nocturnal polyuria impacts 4 out of 5 people with nocturia6-8 Nocturia is an under-recognized condition 1. QuintilesIMS Secondary Resea
Slide 58: Summary point: Nocturia has important consequences
58 Summary point 2 Nocturia has important consequences for health, lifestyle, and work o Nocturia sufferers may have an elevated risk of diabetes, hypertension, coronary heart disease, and death1 o Nocturia significantly impacts daily functioning2,3 o Those who awoke at least 3 nights per week to vo
Slide 59: Summary point: safe and effective nocturia therapy
59 Summary point 3 We finally have a safe and effective nocturia* therapy for both men and women o Noctiva is the first and only FDA-approved treatment for nocturia1* o Noctiva effectively treats nocturia using 1/100th of the desmopressin dosage of other formulations2,3 o Noctiva decreased nocturic
Slide 60: Commercial Strategy and Launch Update
60 Commercial Strategy and Launch Update Greg Divis, Executive Vice President and Chief Commercial Officer Avadel
Slide 61: Highlights
61 Highlights o Market overview o Situation analysis—recent key learnings – Prescriber – Patient – Payer o Brand strategic plan o Launch update and timing o Physician segmentation and field force update o Key financial highlights o Summary
Slide 62: Nocturia market overview
62 Nocturia market overview ~3 M Attractive existing market with significant upside for market expansion ~50% Dx nocturia alone ~50% Dx nocturia with other (OAB/BPH) 6 to 12 million8 annual TRxs $2B+8 current annual market value 1. Bosch JLH, Weiss JP. The prevalence and causes of nocturia. J Urol.
Slide 63: State-level nocturia prevalence rates
63 At a state level, the highest nocturia prevalence rates tend to occur in the Midwest and South Central states 2.95 6.83 10.70 Patients With Nocturia per 1000 Population Source: QI Nocturia Predictive Modeling October 2017 based on Xponent and Claims Databases, MAT July 2017. US Census projected p
Slide 64: Most common treatments for nocturia due to OAB and BPH
64 Anticholinergics and alpha-blockers are the most common treatments for nocturia due to OAB and BPH overlap Sources: Physician interviews, physician survey. July 2017. Physicians will treat patients based upon the presentation and etiology of nocturia • Patients with other comorbidities, such as d
Slide 65: Current branded treatments and price points
65 Current branded treatments and price points Product WAC Package Size VESIcare Oral Tablet 10 mg or 5 mg (same price) $314.77 30 tablets Detrol LA Oral Capsule Extended Release 24 Hour 2 mg $365.00 30 capsules Ditropan XL – Ditropan XL Oral Tablet Extended Release 24 Hour 10 mg $636.12 100 tablets
Slide 66: Situation and insights
66 Situation and insights 400+ 400+ 40+ interviews with urologists, OB/GYNs, UroGYNs, PCPs, NPs, and PAs patients included in qualitative and quantitative studies interviews with P&T committee members within large national and regional MCOs Comprehensive, ongoing market research with HCPs, patients,
Slide 67: HCPs' ability to offer symptomatic relief is variable
67 HCPs’ ability to offer patients symptomatic relief from nocturia is variable Most doctors acknowledge that current treatments don’t work well on nighttime symptoms • Nocturia is typically discovered during routine H&P or “review of systems” and tends to be more frequently talked about directly wi
Slide 68: HCPs believe quality of life is key to addressing nocturia
68 HCPs believe the way to highlight the importance of addressing nocturia is to point out that it can substantially impact QoL They recommend emphasizing individual QoL benefits • Rather than focus on one particular effect of nocturia, HCPs told us that improving the patient’s QoL is the paramount
Slide 69: Impact of nocturia on patients is variable
69 Impact of nocturia on patients is variable: for most, it is frustrating but viewed as a natural consequence of aging Most people experiencing nocturia are unaware that this condition even has a name Variability is driven by: o Frequency of sleep disruptions o Ease of falling back to sleep o Abili
Slide 70: Patients face barriers talking to doctors about nocturia
70 Patients face barriers in talking to doctors about their nocturia—they don’t (yet) have a name for it Why It Gets Raised Why It Does Not Get Raised or Addressed • Patient has other urinary symptoms, particularly daytime symptoms (OAB, BPH) • The patient’s nocturia is very bothersome (multiple voi
Slide 71: Payers do not actively manage or monitor nocturia
71 Payers do not actively manage or monitor nocturia as it is a low-cost area for plans and lower priority overall Source: Payer interviews. July 2017. Current Market Access Environment Management • Low priority is placed on nocturia because it is a low-cost, low-burden lifestyle disease • Coverage
Slide 72: Today versus Future
72 Today No specific treatment for nocturia; payers are focused elsewhere; HCPs and patients are frustrated Future Noctiva – a treatment of choice for nocturia for payers, HCPs, and patients
Slide 73: Our approach: market expansion, specialist-focused, pre-launch
73 Today No specific treatment for nocturia; payers are focused elsewhere; HCPs and patients are frustrated Future Noctiva - a treatment of choice for nocturia for payers, HCPs, and patients Our approach Market Expansion Expand to drive broad market adoption Specialist-Focused Establish leading mark
Slide 74: Overarching launch plan
74 Overarching launch plan Expand to drive broad market adoption Establish leading market position among specialists quickly Energize the market early and often • Shape market by educating high-value HCPs and payers • Ensure positive first experiences for target HCPs and their patients to drive earl
Slide 75: Launch update and timing
75 Launch update and timing Q4’17 Q1’18 Q2’18 Q3’18 Q4’18 Phase 1: Foundation building Phase 2: Disease-state education and early experience Phase 3: Full commercial specialty-focused launch Objectives: o Secure top talent for key positions o Prepare Noctiva for specialty-focused launch, including f
Slide 76: Organizational build update
76 Organizational build update All teams (except sales reps) to be on board by December 2017. Sales team by January 2018 Market Access 4 National Account Managers + contracted team 1 Patient Access and Reimbursement Lead 8 MSLs, contracted 1 Medical Lead, contracted part-time Medical & Clinical Sale
Slide 77: Sales force size and structure
77 Sales force size and structure Source: Avadel/QI - Sales Force Design for Noctiva – HCP Segmentation. HCP Specialty Does an HCP specialty/ practice make them more apt to adopt our therapy? 6 • HCP specialty and practice affiliation 4 • NBRx in the Noctiva market Dynamic Market Volume How likely i
Slide 78: Top nocturia market writers cluster in metropolitan areas
78 As might be expected, top nocturia market writers tend to cluster in metropolitan areas Source: QI Nocturia Segmentation and Predictive Modeling October 2017 based on Xponent and Claims Databases, MAT July 2017. Top Nocturia Writers 1 Dot = 5
Slide 79: Optimized territories cover targeted HCPs
79 80 optimized territories cover ~81% of targeted HCPs and ~90% of all current nocturia diagnosis claims Source: QI Nocturia Segmentation and Predictive Modeling October 2017 based on Xponent and Claims Databases, MAT July 2017.00. Top Nocturia Writers (1 Dot = 5) In Noctiva footprint In Noctiva wh
Slide 80: Key financial updates
80 Key financial updates Transformational opportunity requires significant and disciplined investment •~50% on new teams •~20% on promotional campaign •~20% on educational campaign •~10% on other (data, research, PMR, etc) 2018 launch investment of $50M+ •Expected to be impacted in the first couple
Slide 81: Revenue opportunity
81 Revenue opportunity $250M-400M peak revenue opportunity Assumes 6% to 10% penetration of currently treated pool at peak Maximizing the specialist opportunity will lead to expanding our treater base and building broader condition and Noctiva awareness. $500M-750M+ revenue opportunity Assumes 11% t
Slide 82: Summary
82 Summary Noctiva provides significant growth catalyst and potential value creation opportunity for our shareholders Transformational opportunity for AvadelA Innovative and differentiated productB First and only FDA-approved medication in highly prevalent conditionC Documented serious health-relate
Slide 83: Q&A
Noctiva’ (snopes ea Q&A
Slide 84: Closing remarks
84 Closing remarks Future 2018 and beyond… Present 2012-2017 Past 1990-2012 • Focused on drug delivery and life-cycle plays for large pharma with no internal pipeline or long-term growth strategy • Unprofitable with only one product approval. No organizational direction or growth plan • Profitable w
Slide 85: Thank You
Noctiva’ (snopes ea Thank You
Avadel Pharmaceuticals — Investor Presentation (November 2017) on 6ix